novo nordisk - Search News

News

Novo missed its sales estimates on weight-loss drug Wegovy

Novo Nordisk hopes to see US Wegovy sales recover soon

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after the company cut its 2025 forecasts.

AOL · 1h

Why Novo missed its sales estimates on weight-loss drug Wegovy: CEO

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is losing ground.

Bloomberg on MSN · 12h

Novo Nordisk Gains as CFO Touts Wegovy’s Rebound Potential

Novo Nordisk A/S surged on expectations that some competition for its blockbuster obesity shot Wegovy will subside, paving the way for a sales rebound later this year.

Novo Nordisk shares are rising

MarketWatch on MSN · 6h

Novo Nordisk shares are rising after the company cut its outlook. It’s been that kind of year.

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But that’s reflective of the tough times the Danish maker of Ozempic and other weight-loss drugs has had.

AOL · 10h

Novo Nordisk beats on Q1 earnings, cuts 2025 outlook

Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) with 99 cents per share compared to estimates of 94 cents per share. Sales of the company's blockbuster GLP-1 drugs, up 13% year-over-year, drove the quarter's results, despite a slight slowdown in weight loss sales.

Reuters on MSN · 13h

Novo Nordisk cuts forecasts, shares rise ahead of FDA ban on Wegovy copycats

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) - Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday for the first time since the launch of its Wegovy weight-loss drug four years ago,

9hon MSN

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...

11hon MSN

Novo Nordisk's CFO sceptical Trump executive order on drug manufacturing can cut timelines

Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to ...

18m

Ozempic maker Novo Nordisk set for slimmer sales amid surge in copycat weight-loss drugs

Novo Nordisk, which also makes Wegovy, fell victim to 'compounding' - a practice in the US that allows pharmacies to produce ...

5hon MSN

Why Novo Nordisk Stock Popped After Earnings

Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 ...

11hon MSN

Drugmaker Novo Nordisk drops gender representation requirements in the US

COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for ...

The Economist2h

Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; Novo’s has fallen by as much (see chart 2). Lilly’s edge rests on a more ...

Novo Nordisk Predicts Strong Second Half

Weight-loss drug maker Novo Nordisk reported an earnings beat, but sales fell short of expectations. Novo Nordisk trades for ...

Novo Nordisk Q1 Earnings Review: Forget Revenue Miss, Buy Semaglutide Hype

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

News

Novo missed its sales estimates on weight-loss drug Wegovy

Novo Nordisk shares are rising

Related topics